UV-curable gels as topical nail medicines: in vivo residence, anti-fungal efficacy and influence of gel components on their properties

L V Kerai¹, S Hilton¹, M Maugueret², B B Kazi², J Faull², S Bhakta², S Murdan¹*

¹UCL School of Pharmacy, 29-39 Brunswick Square, London, WC1N 1AX, UK.
²Department of Biological Sciences, Institute of Structural and Molecular Biology, Birkbeck, University of London, Malet Street, London, WC1E 7HX, UK.

*Corresponding author
T +44-207 753 5810
F +44-207-753-5942
E s.murdan@ucl.ac.uk

Keywords: UV gel, acrylate, Ungual, Release, Permeation, Anti-fungal efficacy, In vivo, Residence, Onychomycosis, amorolfine, terbinafine, TOWL
Abstract

UV-curable gels, used as nail cosmetics for their in vivo durability, were reported to be promising as topical nail medicines. Our first aim was thus to investigate whether such durability applies to drug-loaded formulations. This was found to be true. However, ethanol inclusion in the pharmaceutical formulation (to enable drug loading) reduced the in vivo residence. The second aim was therefore to determine any other effects of ethanol, and if ethanol could be avoided by the choice of monomers. Thus, three methacrylate monomers, ethyl methacrylate, isobornyl methacrylate and 2-hydroxyethyl methacrylate (HEMA) were selected, and their influence on the formulation properties were determined. Results: Ethanol and the methacrylate monomer influenced some (but not all) of the formulation properties. The most significant was that HEMA could dissolve drug and enable the preparation of ethanol-free, drug-loaded formulations, which would benefit in vivo residence. The absence of ethanol reduced drug loading, release and ungual flux, but had no negative impact on the in vitro anti-fungal efficacy. Conclusion: judicious selection of gel components enables the exclusion of ethanol. The long in vivo residence, little residual monomers, sufficient ungual permeation and in vitro anti-fungal activity of the gels indicate their potential as anti-onychomycotic topical medicines.
1. Introduction

Onychomycosis which is defined as fungal infection of the nail plate and/or nail bed, is a significant medical burden, affecting 10% of the general population, 20% of those over 60 years old, up to 50% of those over 70 years old and up to one-third of diabetics (Thomas et al., 2010). The disease is often of long duration, is ‘more than a cosmetic problem’ (Scher, 1994), significantly affects patients’ quality of life (Lubeck et al., 1993) and is recalcitrant to treatment (Arrese and Pierard, 2003; Daniel and Jellinek, 2010). Oral therapy with antifungal agents, such as terbinafine and itraconazole, is the treatment mainstay. However, drug efficacy is far from ideal, with pooled mycological cure rates in randomised controlled trials being 76 ±3% for terbinafine and 63% ±7% for itraconazole (Gupta et al., 2004). The disadvantages of oral therapy, such as the potential for adverse systemic effects and drug interactions means that topical therapy is highly attractive, and a number of topical formulations have been tested, patented and a few have been marketed, compiled in, for example (Saner et al., 2014; Shivakumar et al., 2012). Unfortunately, the success rates of topical therapy are even lower, as indicated in the medicines’ patient information leaflets, and compiled in (Murdan, 2016). A number of possible reasons for the low clinical cure of therapy have been proposed, such as inaccurate diagnosis, incorrect antifungal or delivery modality, presence of dormant fungal conidia (which can germinate and give rise to further infection), resistant fungal species, dermatophytoma (areas of the nail filled with debris of keratin and a large amount of fungi material which is more impermeable to drug), low patient compliance, and insufficient drug permeation into and through the nail plate for anti-fungal kill (Baran et al., 2005; Goodfield and Evans, 2000).

Insufficient drug in the nail could be due to the fact that the commercially available topical formulations do not have a continuous residence on the nail plate following application, and thus do not maximise the duration of ungual drug permeation. For example, the most recently marketed formulations Jublia®, Kerydin® and Onytec® are easily washed off, and the patient information leaflets recommend application prior to bedtime to enable ungual drug permeation to occur for at least the duration of sleep (AnacorPharmaceuticals, 2014; KakenPharmaceutical, 2014; Onytec). Loceryl® is meant for weekly application (Galderma, 2014).
2015). However, in vivo experiments have shown that the Loceryl film does not stay intact on the nail for the duration of a whole week, at least on fingernails (Murdan et al., 2015). Non-continuous residence of drug formulations on the nail could be compounded by poor patient compliance. While the latter is not known, the extensive literature on (fairly low) patient compliance in general, suggests that compliance to topical nail medicines is likely to be lower than required.

Patient compliance could be improved by longer-lasting topical formulations and we have previously proposed UV-curable gels as topical formulations which are likely to have long in vivo residence on the nail (Kerai et al., 2015). In the work discussed in this paper, the first aim was thus to investigate the in vivo residence of these formulations. During this study, it was found that, while the UV-cured films have a fairly long in vivo residence, inclusion of ethanol in the formulation (which enabled sufficient drug loading) reduced the in vivo residence. The second aim was therefore to determine what other effects ethanol had, if these effects were independent of the other gel components, and whether the inclusion of ethanol could be avoided.

Cosmetic UV curable gel formulations typically consist of three components: i) a urethane methacrylate, ii) a (meth)acrylate based monomer and iii) a polymerisation photoinitiator. The pharmaceutical UV curable gel formulation reported previously consisted of these, specifically, diurethane dimethacrylate (DUDMA), ethyl methacrylate (as the (meth)acrylate based monomer) and 2-hydroxy-2-methylpropiophenone as the photoinitiator, as well as a drug (amorolfine HCl or terbinafine HCl) and a solvent (ethanol). In order identify more appropriate gel components (to avoid the use of ethanol), one could screen alternative urethane-based methacrylates such as Di-HEMA trimethylhexyl dicarbomate, photoinitiators such as 1-hydroxycyclohexyl phenyl ketone and different (meth)acrylate based monomers. In this work, we decided to keep DUDMA as the backbone of the formulation as it produces a strong film with exceptional abrasion resistance and durability, and 2-hydroxy-2-methylpropiophenone as the photoinitiator, and to screen different methacrylate based monomers. Thus, 2-hydroxyethyl methacrylate (HEMA) and isobornyl
methacrylate (IBOMA), in addition to ethyl methacrylate (EMA) were selected as the methacrylate based monomers. The influence of these monomers and of ethanol on the gel and film properties were determined, and correlations among the different properties of the films formed by photo-polymerisation were explored.

2. Materials and Methods

2.1 Materials

Amorolfine HCl was purchased from Ranbaxy Research Laboratories (Haryana, India) and terbinafine HCl from AK Scientific (CA, USA). Diurethane dimethacrylate, ethyl methacrylate, isobornyl methacrylate, 2-hydroxyethyl methacrylate, 2-hydroxy-2-methylpropiophenone, absolute ethanol, methanol, propan-2-ol, sodium chloride, triethylamine, phosphoric acid 85% wt solution in water and trifluoroacetic acid and a dialysis tubing cellulose membrane (MW 10281) were purchased from Sigma–Aldrich (Dorset, UK). Acetonitrile HPLC gradient grade was purchased from Fisher Scientific (Hertfordshire, UK). A 36 Watt Cuccio Professional UVA nail lamp was purchased from Amazon UK. Nail & Beauty Emporium lint-free wipes (4 ply) were purchased from Just Beauty UK, an online retailer specialising in professional beauty, hair and skin products. Sabouraud dextrose agar was purchased from Oxoid Ltd (Basingstoke, UK). One dermatophyte strain, *Trichophyton rubrum* (CBS 118892), was used. Curanail® nail lacquer was used as a control in some experiments and was purchased from pharmacies in the UK. Human nail clippings (fingernails) were obtained from healthy volunteers aged between 18 and 65 years (following ethics approval).

2.2 Determination of drug (amorolfine HCl and terbinafine HCl) solubility in methacrylate monomers

The saturation solubility of the two drugs in EMA, HEMA and IBOMA was determined as described in (Kerai et al., 2015).
2.3 Preparation of UV gels and films

Drug-free gel formulations were prepared by mixing DUDMA with a methacrylate monomer (EMA or IBOMA or HEMA) at 85:15 or 75:25 (for HEMA only) v/v ratios, the photoinitiator at 3% v/v of the methacrylate mixture, with or without ethanol at 25% v/v of the methacrylate mixture, and leaving the mixture to stir overnight, which produced a clear homogenous solution. Drug-loaded formulations were prepared by first dissolving the drug in ethanol, and then adding the methacrylates and photoinitiator and leaving the mixture to stir overnight, which also produced a clear homogenous solution. To prepare the films, the gel mixture was applied on a microscope glass slide using a pipette tip (30 µl to an area of 15 mm x 15 mm as a single layer), which was then placed under the UVA lamp for two minutes. This caused curing of the formulation and formation of a film. The surface of the film was wiped with propan-2-ol using a super absorbent 4 ply lint-free nail wipe to remove the oxygen inhibition layer (an unreacted monomer layer). This revealed a glossy polymer film, which was then removed from the glass slide using a scalpel and characterised.

A curing time of 2 minutes was selected after experimenting with 0.5-5 minutes of UVA exposure, and measuring the gel blend to polymer film mass yield, the alkene-to-alkane degree of conversion (the route of polymerisation), and the levels of residual monomers in the polymer film. The measurements (Supplementary Data 1a) showed that a cure time of two minutes was sufficient for maximal mass yield and degree of conversion and for minimal residual monomers.

2.4 In vitro characterisation of the gels and UV-cured films

The in vitro properties of the gels and of the films, such as gel viscosity, maximum drug loading, gel-to-film mass yield, degree of conversion and the films’ appearance, microstructure, crystallinity, level of residual monomers, drug-polymer interactions, glass transition temperature, adhesion, water sensitivity, drug release and ungual permeation were determined as described in (Kerai et al., 2015). The films’ mass change with time was monitored over 28 days under the following testing conditions: 30°C ± 2°C and 50% RH ± 5%
RH, by placing the films in a desiccator containing a saturated solution of magnesium nitrate and placing this in a 30°C oven. The film’s mass was recorded on days 0, 1, 2, 3, 7, 14, 21 and 28. The film thickness was measured using a Sealey AK9635D 0–25 mm Digital External Micrometer (PVR Direct, Bristol, UK). Each film was measured at three separate points and an average was taken, and each test was carried out in triplicate. Precautions were taken to measure the thickness without compressing the polymer film. The uniformity of thickness within each film and between films was calculated using the following formula:

\[
\% \text{ Uniformity} = (1 - \frac{\text{standard deviation}}{\text{mean}}) \times 100
\]

2.5 In vivo fingernail residence of UV-cured polymer films

Following approval by the UCL School of Pharmacy’s ethics committee (Project 5337/002), 12 volunteers (aged between 18 – 65 years) with healthy fingernails were recruited. For each volunteer, a single layer of the UV-curable gel formulation was applied on the five fingernail plates of one hand using a pipette tip, leaving a formulation-free margin (approximately 1-2 mm) near the nail plate perimeter, ensuring that skin contact was avoided. This hand was then placed under a UVA nail lamp for two minutes. Subsequently, the surface of the cured gel on each nail plate was wiped with propan-2-ol using a super absorbent nail wipe to remove the oxygen inhibition layer, leaving behind a thin, smooth, transparent film. The procedure was repeated on the other hand. The nails were visually observed daily to estimate the percentage of UV-cured film remaining on the fingernails. Estimation was facilitated by visually dividing the nail plate into quadrants which were then further divided into sub-quadrants. Daily observation was continued until the UV-cured films had completely dislodged from the nail plate or for up to 28 days, whichever was sooner. After 28 days, the remaining film was removed using a wooden stick 10 minutes following the application of a cotton pad soaked with acetone over the film. The experiment was then repeated with a different formulation. A total of four UV-curable gel formulations (which contained the monomer EMA, ± solvent and drug) were tested, and each formulation was tested on a minimum of six volunteers.
2.6 In vivo occlusivity of UV-cured polymer films

The occlusivity of UV-cured films was assessed by measuring trans-onycheal water loss (TOWL) from the healthy fingernail plates of volunteers before and after the application of the gel formulations (which were applied as described in Section 2.5). Curanail® lacquer film was used as control, and was applied as instructed in the packaging (i.e. after filing and cleansing). Prior to TOWL measurements, the volunteers had rested for at least 60 minutes in the laboratory, and avoided contact with water. TOWL measurements were obtained using a Biox Aquaflux Model AF200 equipped with an in vivo nail cap (Biox Systems Ltd, London, UK). The finger was placed on a flat surface for support and the Aquaflux measurement head was placed on the centre of the nail plate. No pressure was applied as the weight of the measurement head itself ensured a good seal, and measurements were collected using AquaFlux version 4.8. Water vapour flux density versus time curves were recorded until a steady-state TOWL reading was obtained (between 90 - 120 seconds, with a mean of 10 points), and five repeats were obtained per formulation. All measurements were conducted in the same laboratory, where the ambient temperature and air humidity fluctuated between 22 - 26°C and 38 - 48% respectively. The % reduction in TOWL was calculated as follows:

\[
\text{% Reduction in TOWL} = \frac{\text{TOWL (before formulation application)} - \text{TOWL (after formulation application)}}{\text{TOWL (before formulation application)}} \times 100
\]

A greater reduction in TOWL indicates higher occlusivity of the film.

2.7 In vitro antifungal efficacy of UV gels against T. rubrum

The dermatophyte T. rubrum was chosen as it is the most common causative organism of onychomycosis. The ability of the formulations to inhibit fungal growth was used as a measure to compare formulations. The classical disc diffusion method was adapted, where the ‘disc’ was replaced by a circular piece of nail clipping onto which a gel formulation had been cured, taking care to leave a formulation-free margin at the nail edge, such that the drug would have to be permeate into and through the nailplate to reach the agar gel. This
method was used as there is currently no standard in vitro method to assess the anti-fungal efficacy of anti-onychomycotic formulations.

Preparation of SDA plates: A Sabouraud Dextrose Agar (SDA) solution (65 g SDA/L of distilled water) was prepared, sterilised (by autoclaving at 121°C for 15 minutes) and poured into 90mm petri dishes (25 ml of agar solution/dish) and allowed to solidify overnight.

Preparation of test plates: A cork borer (8mm-internal diameter, sterilised by dipping in ethanol then flamed) was punched into the centre of a SDA plate (prepared above) to remove a plug of agar, which was discarded. The cork borer was sterilised once more, and used to punch out a T. rubrum plug from a fresh culture plate of T. rubrum. The fungal plug was inserted into the slot created in the first SDA plate, and the latter was then incubated at 32°C for three days to ensure that the fungal culture grew sufficiently and to identify (and remove) defective plates, if any. During this time, the T. rubrum culture grew to 10 mm in diameter.

Preparation of nail clippings with drug formulations: Human fingernail clippings were washed with water, cut to size (circular, with a diameter of 3 mm) and autoclaved at 120°C for 20 minutes in order to sterilise them (autoclaving did not affect the nail properties - indicated by the lack of change in solvent uptake). Two µl of a formulation was applied on the nail surface, ensuring a small formulation-free perimeter at the edge of the nail surface. For the control Curanail, the lacquer was allowed to air-dry. For the UV gels, the nail was placed under an UVA lamp for 2 minutes, after which the surface of the film produced was wiped with propan-2-ol using a nail wipe.

Details of the formulations tested are shown in Table 1. Drug-free counterparts of these formulations were also tested to assess the influence, in any, of the UV-cured film itself against T. rubrum. In addition, Curanail® nail lacquer (containing 5% w/v amorolfine HCl) was tested as a positive control.

Evaluation of anti-fungal efficacy: Three days following the insertion of the fungal plug into a prepared SDA plate, the latter was marked into four quadrants (which enabled the testing of one test formulation on three nail clippings, and one drug-free formulation on a fourth nail clipping per plate). Using a sterile tweezer, the prepared nail clippings were carefully
placed on the agar gel surface at a distance of 20 – 25 mm from the centre of the plate. This distance was chosen to allow sufficient time for the drug to penetrate into and through the nail into the agar gel, based on the ungual drug permeation results and *T. rubrum* growth rates from preliminary studies. Thus, each plate contained a triplicate set of the same formulation in addition to a drug-free control.

In addition to the test plates, two controls were set up: i) a formulation-free, nail-free negative control was set up to monitor the growth of *T. rubrum*, and ii) a control plate containing 3 equally-spaced nail clippings with drug-free UV-cured films on their surface, with the clippings being placed at a distance of 20 – 25 mm from the centre of the plate.

The SDA plates were incubated at 32°C for as long as it took the *T. rubrum* culture to grow over the entire SDA plate’s surface (or when no further growth was detected). During this period, the plates were observed daily to monitor the growth of *T. rubrum* and to monitor the formation of a zone of inhibition, if any, around the nail clippings.

### 2.8 Statistical analysis

All the experiments described above were repeated three times (except for the *in vitro* drug permeation study which was repeated six times, in vivo residence studies where *n*=60 (10 fingernails x 6 volunteers) and in vivo TOWL measurements where *n*=5). Statistical calculations were conducted using SPSS 22. Repeated measures ANOVA and post hoc Tukey tests were performed on the drug release, ungual permeation and in vivo residence profiles over time. When *n* ≥5, Students t-tests were performed to compare two data sets while ANOVA, with post hoc Tukey were conducted to compare more than two data sets. Non-parametric tests were used when *n*=3; specifically, Mann-Whitney to compare two groups, and Kruskal-Wallis, followed by Nemenyi’s tests to compare more than two groups.

### 3. Results and Discussion

#### 3.1 In vivo residence of UV-cured films
The in vivo residence of UV-cured films, and of Curanail nail lacquer (used as a commercially available control) is shown in Figure 1. It can be seen that the UV-cured films have a much longer residence on the nail compared to Curanail (p<0.05). Four weeks after gel application and film formation, a considerable proportion of the film remained on the nails. This shows that the UV-cured films have promise as long-term topical nail medicines, continuously allowing drug to permeate into the nail, and thereby improve the success of topical nail medicines. A longer residence on the nail could also improve patient compliance as less frequent drug application will be needed.

The longer residence of the ethanol-free UV-cured formulation compared to ethanol-containing ones (p<0.05) indicates that ethanol-free pharmaceutical formulations would be advantageous for nail medicines. The presence of ethanol had enabled drug loading in the formulations and had influenced some, but not all of the formulation properties investigated (Kerai et al., 2015). In order to further explore the influence of ethanol on the formulation properties and determine whether such influence was independent of the nature of the other gel components, and evaluate the possibility of developing ethanol-free formulations, two additional methacrylate-based monomers (in addition to ethyl methacrylate) were selected and their formulations were characterised as discussed below.

### 3.2 Selection of the nature and proportion of the methacrylate monomers in the gel

In contrast to cosmetic UV gels examined, which contain a mixture of acrylate- and methacrylate-based monomers, only methacrylate-based monomers were included in our pharmaceutical formulations due to their lower toxicity and lower sensitising capacity (Clemmensen, 1984; Rietschel et al., 2008; Yoshii, 1997), which render them more favourable for nail products (Schoon, 2010). Of the possible methacrylate-based monomers, ethyl methacrylate (EMA), hydroxyethyl methacrylate (HEMA) and isobornyl methacrylate (IBOMA) were selected due to their unique structures (Figure 2), which could differently impact the resulting films’ properties, and which would, in turn, enable the exploration of correlations among the formulation properties. EMA was expected to enhance film
flexibility, IBOMA – with its cyclic group – could affect the resulting film’s mechanical strength and glass transition temperature while HEMA – with its hydroxyl group – could affect the hydrophilic/hydrophobic character of the resulting film. The three monomers also have different solvencies for the two drugs being tested (Table 2), and the higher solvency of HEMA towards the drugs enables the development of ethanol-free gels.

The ratio of diurethane dimethacrylate (DUDMA) to methacrylate monomer (EMA or HEMA or IBOMA) in the gel formulations were generally kept at 85:15 % v/v as in (Kerai et al., 2015), except for the ethanol-free HEMA-based formulations. As HEMA could dissolve the drugs to some extent (Table 2), it was possible to produce drug-loaded gels without ethanol. In this case, the proportion of HEMA was increased to enable sufficient drug loading. Thus HEMA-containing formulations were also produced at a DUDMA:HEMA ratio of 75:25 %v/v.

The photoinitiator (2-hydroxy-2-methylpropiophenone) was kept at 3% v/v of the methacrylate mixture as this was found to be sufficient for maximal gel-to-polymer degree of conversion and mass yield and minimal levels of residual monomers (supplementary data 1b). Ethanol was included at a concentration of 25% v/v as this concentration increased the formulations’ drug loading and did not compromise the films’ water-resistance (Kerai et al., 2015). Ethanol-free formulations of HEMA were also produced.

3.3 Influence of gel components on its properties

3.3.1 Gel viscosity: The viscosities of the gels (± ethanol and ± drug) are shown in the Supplementary Data 2. In ethanol-free gels, the nature and proportion of the methacrylate monomer had a direct influence on viscosity (p<0.05), which was between 162 mPas and 672 mPas. Inclusion of ethanol (whose viscosity is 1 mPas) considerably reduced the gel and all ethanol-containing gels (with/without drug) had similar viscosities of 15-25 mPas (p>0.05). Inclusion of the very low viscosity ethanol overrides any influence of the
methacrylate monomer on gel viscosity. Gel viscosity is an important parameter: too high viscosity will cause difficulty during gel application, while insufficient viscosity will result in the gel spreading from the nail plate into the nail folds. Excessive gel spreading is undesirable to avoid contact between the gel (containing potentially allergenic and sensitising monomers) and the skin. The viscosities of these gels are deemed to be appropriate as the gel could be applied to the nail in volunteers, without any problems (Section 2.5).

3.3.2 Drug loading and stability in gels: Drug loading in a gel (Table 3) depended on the drug’s solubility in ethanol and in the methacrylate-based monomer, the drugs being insoluble in DUDMA (Kerai et al., 2015). Thus, gels containing HEMA and ethanol dissolved the most drug due to the greater drug solvency of HEMA. Terbinafine loading was higher than that of amorolfine, due to its greater solubility in ethanol (Kerai et al., 2015). Over a period of six months, all the drug-loaded gels (stored under accelerated stability conditions) showed no change in colour, no visible signs of drug precipitation, and no change in drug concentration. The UV-curable gel formulations were therefore considered stable and suitable for further development.

3.3.3 Polymerisation, degree of conversion and levels of residual monomers: Exposure of the gels to UVA initiates polymerisation between DUDMA and the methacrylate-based monomer (EMA or IBOMA or HEMA), where the original alkene bonds in the acrylate moieties are converted to alkane ones. The degree of alkene-to-alkane conversion (DC) was between 56% and 68% (Supplementary data 3a). Ethanol inclusion in the gels led to significantly higher \( p<0.05 \) degrees of conversion, possibly due to the lower gel viscosities, which could have enabled increased reaction among the more mobile reactants. In contrast, the nature of the methacrylate-based monomer (EMA, IBOMA, HEMA) and the presence of drug did not influence DC \( p>0.05 \).
Very low levels of residual monomers (≤1% DUDMA, ≤ 0.005% EMA, ≤0.004% IBOMA and ≤0.005% HEMA) were found in drug-containing films (Supplementary data 3b), which indicates that the much less than 100% alkene-to-alkane degrees of conversion seen are due to the presence of unreacted alkene groups within the polymer, rather than unreacted monomers. It appears that most of the methacrylate monomers in the UV gel are involved in the polymerisation process, while a large number of the alkene groups are not. The very low levels of residual monomers make the films attractive drug carriers, as the potential for allergic reactions (which is linked to monomers) is reduced.

3.4 Influence of gel components on the properties of the UV-cured films

3.4.1 Film macro-and micro-structure, amorphicity, FTIR: All the UV-cured films (irrespective of monomer nature, and presence or absence of ethanol and of drug) were visually smooth, transparent, had uniform thickness (≥95%), were amorphous, and were aesthetically acceptable as topical drug carriers. Scanning electron microscopy revealed a generally rough film surface on the side that was exposed to UV light, a much smoother surface where the film had been formed in contact with the support and a fairly dense film cross-section (Figure 3). Film thickness was about 200 µm, with no influence of drug or of nature of the monomer (p>0.05). Inclusion of ethanol significantly (p<0.05) reduced film thickness to about 165 µm, due to the formulations’ lower methacrylate content. FT-IR of the films showed no drug-polymer interactions.

3.4.2 Drug loading and stability: Drug in the film was in the dissolved state, and its concentration in the film was similar to that in the gel shown in Table 3 (p>0.05). Upon storage of the films for 28 days under accelerated stability conditions, the drug levels remained the same, and the drug remained dissolved for at least two weeks, with a few drug crystals appearing in week 3. There were no differences among films with/without
ethanol, with/without drug and containing the different methacrylate-based monomers (Supplementary data 4).

**3.4.3 Glass transition temperatures of films.** The films produced from ethanol-free formulations showed two transition temperatures (Table 4). It is thought that the lower Tg value is the polymer’s Tg caused by UV curing of the gel mixture, and that the second Tg is related to a thermal cure which occurred during the DMA measurement. The UV-cure related Tg is influenced by the nature of the methacrylate-based monomer, with EMA-based gel having higher Tg than HEMA-based one, which in turn had higher Tg than IBOMA-based one (p<0.05). Such a difference in gel Tgs could be due to their different viscosities, which were 367 mPas, 598 mPas and 672mPas for EMA-, HEMA- and IBOMA- based gels respectively. The negative correlation between gel viscosity and polymer Tg can be explained by the fact that, in a reaction mixture with lower viscosity, reactants are likely to be more mobile, which would increase the likelihood of polymerisation and of cross-linking and which would in turn increase the resulting polymer’s Tg.

Inclusion of ethanol in the formulation had a major influence on the films’ glass transition temperatures, resulting in films with only one Tg, and increasing the UV-cure Tg (p<0.05). The higher Tgs reflect the greater extent of polymerisation (shown by higher degrees of conversion and lower levels of residual monomers in Supplementary Data 3b) in ethanol-containing formulations and could also be a result of these gels’ much lower viscosities.

**3.4.4 In vitro adhesion and water sensitivity of films:** In contrast to the in vivo situation where the presence of ethanol reduced the in vivo residence of the films (Figure 1), the three in vitro tests used (Instron pull-off, the cross-cut and water sensitivity) showed no influence of ethanol, or of the nature and concentration of the methacrylate monomer on film adhesion and water sensitivity (p>0.05, Supplementary data 5). It seems that DUDMA (present at a much higher content than the methacrylate monomer in the film) is the main factor responsible for the adhesion and water-resistance properties of the films in vitro.
3.4.5 *In vitro drug release:* Drug release profiles (Figures 4-5) of all the UV-cured films (containing the maximum amount of drug that could be loaded in the dissolved state in each film) showed a burst release over the first 24 hours, followed by a slower phase, followed by a plateau. Examination of the films at the end of the release study showed negligible change in film mass over the study duration and no drug precipitation. Fitting of the release data using zero order, first order and Higuchi models showed the best fit to be the Higuchi model ($r^2 \geq 0.8$), indicating drug release to be diffusion-controlled through the film matrix following the burst release phase.

For both drugs, release was incomplete over the 30-day experiment as shown when % drug release was plotted against time (Supplementary data 6). The amorolfine-containing films released about 46% of their drug load, while the terbinafine-containing films released about 26% of their drug load during the 30-day study. The reason(s) for the greater amorolfine release is as yet unclear. The respective amorolfine- and terbinafine- loaded gels have similar reactants-to-film mass conversion, alkene-to-alkane degree of conversion, film thickness, glass transition temperatures, water sensitivity and dense internal structure. It is possible that terbinafine binds to a greater extent to the polymer film compared to amorolfine, which would hinder its release.

In addition to the nature of the drug, the nature of the methacrylate-based monomer also has an impact on the extent of drug release, via its influence on drug solvency, and consequently, on drug loading in the film. Films produced using EMA and IBOMA (both non-solvents for the drugs) contained the same drug loadings (3% amorolfine or 4% terbinafine), which was solely due to the presence of the ethanol. In contrast, films produced using HEMA (a solvent for the drugs) could have a certain drug loading in the absence of ethanol (2% of amorolfine or of terbinafine), and the drug loading was considerably increased in the presence of ethanol (to 4% amorolfine or 6% terbinafine). As the release studies were conducted using films containing the maximum drug loading, the drug concentrations in the films varied from 2% to 4% for amorolfine, and from 2% to 6% for terbinafine. For both drugs, the highest release was obtained from the films containing the highest drug...
concentration, i.e. the film containing HEMA and ethanol (p<0.05, Figures 4-5). Drug concentration in the film is thus an important parameter governing the extent of drug release. Both the nature of the methacrylate-based monomer and the inclusion of ethanol influenced drug release, via their influence on drug concentration in the film.

When drug release from the control Curanail lacquer film was examined, it was found that like the UV-cured films, the Curanail lacquer film containing amorolfine also showed a burst of drug release (Supplementary data 6a). In contrast to the UV-cured films however, the Curanail polymer film released most of its drug load, possibly due to the fact that the film disintegrated during the 30-day study.

3.4.6 In vitro ungual drug permeation: The ungual drug permeation profiles and the permeation parameters are shown in Figures 6-7 and Table 5. Mass balance calculations are shown in Supplementary Data 7. The fairly lengthy lag times in Table 5 are typical of ungual permeation (McAuley et al., 2016) and are due to the poor permeability of the nailplate. The latter is also evidenced by the very small percentage (maximum of 6%) of applied drug which permeated into and through the nail (Supplementary Data 7).

Examination of the ungual permeation profiles shows significant influence of the drug nature and concentration, with amorolfine and the higher drug loadings resulting in greater ungual permeation (p<0.05). Thus, amorolfine-containing formulations showed significantly higher steady-state flux and permeability coefficient (p<0.05) compared to the respective terbinafine-containing ones. This reflects the greater amorolfine released (discussed in section 3.4.5), and thereby its greater availability for ungual permeation. An additional cause for the higher amorolfine permeation could be its lower affinity to nail keratin, compared to that of terbinafine (Tatsumi et al., 2002). Drug-keratin affinity could also explain the similar drug-in-nail concentrations at the end of the permeation experiments (p>0.05; Table 5) despite the lower terbinafine release from the films.
For both drugs, drug loading in the film was the maximum possible (while keeping the drug dissolved) and was related to the nature of the methacrylate-based monomer, and the presence of ethanol as discussed in section 3.4.5. From Figures 6-7, it can be seen that as drug concentration in the film increased, drug permeation increased. This reflects the greater amounts of drug released at the highest drug loadings (section 3.4.5) and consequently, greater drug availability for ungual permeation. Thus, the choice of the monomer and addition of ethanol had important consequences on ungual drug permeation, with the addition of ethanol to HEMA-based formulations significantly increasing drug loading and flux (p<0.05).

The ungual permeation of amorolfine from the control Curanail was similar to that from the ‘best’ UV-cured film (p>0.05 for the permeation curve, permeability coefficients, diffusion coefficients and drug-in-nail at day 30). Curanail® nail lacquer however showed a slightly greater steady-state flux (p<0.05) probably due to its higher drug-load (32% w/w in the film vs. 4% w/w) and much greater drug release (shown in Supplementary Data 6a). However, the UV-cured film displayed a shorter lag time possibly due to its greater occlusivity compared to the lacquer film (Fig. 9), which could increase nail hydration, which is known to enhance permeation (Gunt and Kasting, 2007; Gunt et al., 2007).

3.4.7 In vitro anti-fungal efficacy: The in vitro anti-fungal efficacy of the formulations was measured using an anti-fungal whole cell phenotypic assay, that we adapted from the classical disc diffusion method, in our laboratories. In the negative controls (i.e. where a drug-free formulation was cured onto a nail clipping), the T. rubrum culture grew over the entire plate’s surface (Table 6). In contrast, no T. rubrum growth was observed when drug-loaded formulations had been cured on the nail clippings. This shows that sufficient anti-fungal drug was released from the UV-cured film, permeated into the nailplate, and subsequently permeated out of the nail plate and into the agar gel to inhibit fungal growth. The UV-cured gels are thus promising topical carriers for anti-onychomycotic drugs.
All the gels tested showed complete inhibition of fungal growth (example shown in Table 6), and no difference could be discerned among the formulations (in Supplementary data 7). This could be related to the fact that the amounts of drug present in the nail and that had permeated through the nail plate were fairly similar for all the formulations (as shown in Figures 6-7). In these anti-fungal assays, the ethanol-free gels with the lowest drug load was as good as the ethanol-containing gels with the highest drug load. It seems that the increased drug loading afforded by the inclusion of ethanol in the gels, which results in increased flux was not necessary for anti-fungal kill in this in vitro set-up. Optimisation of the in vitro anti-fungal methodology is needed and it might enable discrimination among the formulations or confirm anti-fungal equivalence despite different drug loadings, release and ungual permeation.

3.4.8 In vivo occlusivity of the UV-cured films: The UV-cured films reduced trans-onychear water loss (TOWL) by about 40% (Figure 8), and were more occlusive than the control Curanail lacquer film. Occlusion is desirable, as a reduction in TOWL has been hypothesised to hyper-hydrate the nail plate (Marty, 1995; Spruit, 1971), which is in turn beneficial for ungual drug permeation (Gunt and Kasting, 2007; Gunt et al., 2007). A second benefit of increased nail plate hydration in the treatment of onychomycosis is that hydration could induce the germination of drug-resistant fungal spores into drug-susceptible hyphae, which would enable fungi eradication (Flagothiser et al., 2005). From Figure 8, it can be seen that ethanol or drug or the nature of the methacrylate monomer in the UV-cured films did not have any influence on the films’ occlusivity (p>0.05). This indicates that DUDMA (present in the film at a much higher content than the methacrylate monomer) is the main factor responsible for the occlusivity of the films.

4. Conclusions

Drug-loaded diurethane dimethacrylate-based UV gels, with or without ethanol, and containing one of three different monomers (EMA, IBOMA or HEMA) were produced and characterised to determine the influence of the monomers, ethanol and drugs on the gel
and resulting films’ properties, and to explore correlations among the films’ characteristics. The drugs – amorolfine HCl and terbinafine HCl – had negligible influence on the films’ properties, except for the extent of their release and ungual flux, with amorolfine release from the film and ungual flux being much higher compared to that of terbinafine. The major influence of ethanol was its ability to increase drug loading, reduce gel viscosity, increase polymerisation and alter the films’ Tg. The greater drug loading enabled by ethanol resulted in higher drug release and ungual flux. However, ethanol inclusion had a negative impact on the film’s in vivo residence, which shows the importance of screening the other methacrylate monomers in order to identify suitable ones. The major difference among the monomers was the fact that HEMA dissolves the drugs to some extent and enabled sufficient drug loading, such that ethanol-free formulations could be developed. All the formulations inhibited anti-fungal growth to the same extent i.e. fully, and differences among the formulations regarding anti-fungal efficacy could not be discerned in the tests used i.e. there was no influence of methacrylate monomer nature, ethanol inclusion and drug concentration on anti-fungal activity. The UV gels’ anti-fungal activities and long in vivo residence further show the promise of these formulations as nail medicines.

Acknowledgments

The authors thank the UCL School of Pharmacy and Birkbeck, University of London for funding this work. We are also grateful for the volunteers for donating their nail clippings and for participating in the in vivo studies.

References

Anacor Pharmaceuticals, 2014. Kerydin Highlights of Prescribing Information, US.
Clemmensen, S., 1984. Cross-Reaction Patterns in Guinea Pigs Sensitised to Acrylic Monomers. 7, 527-540.
21


Kaken Pharmaceutical, 2014. Jublia Highlights of Prescribing Information, US.


Onytec, Package leaflet: Information for the user Onytec 80 mg/g medicated nail lacquer, Ireland, p. Patient Information Leaflet.


**Figure legends**

Figure 1: *In vivo* residence of UV-cured films (± ethanol and ± drug) on the ten fingernails in six volunteers. Curanail lacquer (containing amorolfin HCl) was used as a commercially available control. Abbreviations: ETOH – ethanol; AH – amorolfin HCl; TH – terbinafine HCl. Means and standard deviations are shown, n=60.

Figure 2: Chemical structures and viscosities of the different methacrylate-based monomers.

Figure 3: Scanning electron micrographs of the top surface (i.e. exposed to UV light), under surface (i.e. in contact with the support), and cross-sectional surface of a drug-free, ethanol-free UV-cured film (DUDMA:HEMA 85:15). Films with the other methacrylate monomers, and ± ethanol and ± drug (amorolfin HCl or terbinafine HCl) had similar micrographs.

Figure 4: Cumulative amount of drug release from the amorolfin HCl loaded UV-cured films. Means and standard deviations are shown, n=3. Abbreviations: AH, amorolfin HCl; ETOH, ethanol.

Figure 5: Cumulative amount of drug release from the terbinafine HCl loaded UV-cured. Means and standard deviations are shown, n=3. Abbreviations: TH, terbinafine HCl; ETOH, ethanol.

Figure 6: Cumulative amount of amorolfin HCl permeated across the nail with time from the UV-cured and Curanail® films, and the % of drug permeated across the nail and remaining in the nail at day 30. Means and standard deviations are shown, n=6. Abbreviations: AH, amorolfin HCl; ETOH, ethanol.

Figure 7: Cumulative amount of terbinafine HCl permeated across the nail with time from the UV-cured films, and the % of drug permeated across the nail and remaining in the nail at day 30. Means and standard deviations are shown, n=6. Abbreviations: TH, terbinafine HCl; ETOH, ethanol.

Figure 8: Reduction of TOWL by the different UV-cured films and the Curanail lacquer film control. Means and standard deviations are shown. n=5
Table 1: Table shows details of test formulations used for anti-fungal efficacy assessment. In addition, drug-free counterparts of these and Curanail were used as controls.

<table>
<thead>
<tr>
<th>Nature of monomer</th>
<th>Ethanol concentration</th>
<th>Drug nature and concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>EMA</td>
<td>25%</td>
<td>Amorolfine HCl; 3%</td>
</tr>
<tr>
<td>IBOMA</td>
<td>25%</td>
<td>Amorolfine HCl; 3%</td>
</tr>
<tr>
<td>HEMA</td>
<td>25%</td>
<td>Amorolfine HCl; 4%</td>
</tr>
<tr>
<td>HEMA</td>
<td>None</td>
<td>Amorolfine HCl; 2%</td>
</tr>
<tr>
<td>HEMA</td>
<td>25%</td>
<td>Terbinafine HCl; 6%</td>
</tr>
</tbody>
</table>
Table 2  Solubilities of amorolfine HCl and terbinafine HCl in the three methacrylate monomers; means and standard deviations are shown, n=3.

<table>
<thead>
<tr>
<th></th>
<th>EMA</th>
<th>IBOMA</th>
<th>HEMA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amorolfine HCl</td>
<td>0.10 ± 0.01</td>
<td>0.19 ± 0.02</td>
<td>209.3 ± 9.4</td>
</tr>
<tr>
<td>Terbinafine HCl</td>
<td>0.66 ± 0.19</td>
<td>0.12 ± 0.02</td>
<td>229.0 ± 9.8</td>
</tr>
</tbody>
</table>
The theoretical (based on drug solubility in the gel components) and actual (determined by the absence/presence of drug crystals in the formulation) drug loadings were fairly similar for all the gels except for ethanol-free HEMA-containing gels, where the actual drug-load was much lower than anticipated, due to drug precipitation upon mixing with DUDMA and the photoinitiator.

<table>
<thead>
<tr>
<th>Solvent</th>
<th>Methacrylate-based monomer</th>
<th>Drug</th>
<th>Expected Drug load (% w/v)</th>
<th>Actual drug load (% w/v)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethanol (25% v/v)</td>
<td>EMA</td>
<td>AH</td>
<td>3.0</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TH</td>
<td>3.5</td>
<td>4</td>
</tr>
<tr>
<td>IBOMA</td>
<td></td>
<td>AH</td>
<td>3.0</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TH</td>
<td>3.5</td>
<td>4</td>
</tr>
<tr>
<td>HEMA</td>
<td></td>
<td>AH</td>
<td>5.2</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TH</td>
<td>6.0</td>
<td>6</td>
</tr>
<tr>
<td>None</td>
<td>HEMA</td>
<td>AH</td>
<td>5.1</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TH</td>
<td>5.6</td>
<td>2</td>
</tr>
</tbody>
</table>
Table 4: Transition temperatures (Tg) of UV-cured films. Means ± standard deviations are shown, n=3.

<table>
<thead>
<tr>
<th>Excipients</th>
<th>DUDMA 85 % v/v : diluent monomer 15 % v/v</th>
<th>Formulations</th>
<th>Solvent Ethanol</th>
<th>Drug</th>
<th>EMA</th>
<th>IBOMA</th>
<th>HEMA</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>None</td>
<td>DUDMA</td>
<td>None</td>
<td>None</td>
<td>85.7 ± 1.2 and 146.0 ± 2.5</td>
<td>67.2 ± 2.4 and 164.0 ± 0.2</td>
<td>74.4 ± 2.5 and 147.2 ± 0.3</td>
</tr>
<tr>
<td>25% v/v</td>
<td>None</td>
<td>DUDMA 85 % v/v : diluent monomer 15 % v/v</td>
<td>None</td>
<td>AH</td>
<td>112.5 ± 1.8</td>
<td>139.2 ± 9.0</td>
<td>98.1 ± 2.3</td>
</tr>
<tr>
<td></td>
<td>None</td>
<td></td>
<td>None</td>
<td>TH</td>
<td>109.6 ± 0.8</td>
<td>133.4 ± 3.6</td>
<td>94.7 ± 4.8</td>
</tr>
<tr>
<td>None</td>
<td>None</td>
<td>DUDMA 75 % v/v : diluent monomer 25 v/v</td>
<td>None</td>
<td>AH</td>
<td>95.1 ± 1.5</td>
<td>NF</td>
<td>NF</td>
</tr>
<tr>
<td></td>
<td>None</td>
<td></td>
<td>None</td>
<td>TH</td>
<td>94.8 ± 2.0</td>
<td>NF</td>
<td>NF</td>
</tr>
<tr>
<td></td>
<td>None</td>
<td>DUDMA 75 % v/v : diluent monomer 25 v/v</td>
<td>None</td>
<td>AH</td>
<td>NF</td>
<td>NF</td>
<td>81.8 ± 0.5 and 142.6 ± 0.4</td>
</tr>
<tr>
<td></td>
<td>None</td>
<td></td>
<td>None</td>
<td>TH</td>
<td>NF</td>
<td>NF</td>
<td>92.0 ± 0.9 and 138.9 ± 0.5</td>
</tr>
<tr>
<td></td>
<td>None</td>
<td>DUDMA 75 % v/v : diluent monomer 25 v/v</td>
<td>None</td>
<td>AH</td>
<td>NF</td>
<td>NF</td>
<td>92.4 ± 0.4 and 133.2 ± 0.2</td>
</tr>
<tr>
<td>Tg of homopolymers (°C)</td>
<td>-</td>
<td></td>
<td>-</td>
<td>-</td>
<td>65</td>
<td>110</td>
<td>57</td>
</tr>
</tbody>
</table>
Table 5  Ungual permeation parameters. Lag time, steady-state flux, permeability coefficient, diffusion coefficient and amount of drug in nail clippings. Means and standard deviations are shown, n=6. Abbreviations: AH, amorolfine HCl; TH, terbinafine HCl; ETOH, ethanol.

<table>
<thead>
<tr>
<th></th>
<th>Amorolfine HCl (AH)</th>
<th></th>
<th>Terbinafine HCl (TH)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>% in formulation (% w/v)</td>
<td>Lag time (day)</td>
<td>Steady-state flux (µg/cm²/day)</td>
<td>Permeability coefficient x 10⁻⁵ (cm/day)</td>
</tr>
<tr>
<td>Curanail® nail lacquer</td>
<td>5</td>
<td>10.4 ± 1.3</td>
<td>2.9 ± 0.2</td>
<td>5.8 ± 0.3</td>
</tr>
<tr>
<td>DUDMA &amp; EMA gel containing ETOH &amp; AH or TH</td>
<td>3</td>
<td>10.4 ± 0.9</td>
<td>2.4 ± 0.2</td>
<td>7.9 ± 0.7</td>
</tr>
<tr>
<td>DUDMA &amp; IBOMA gel containing ETOH &amp; AH or TH</td>
<td>3</td>
<td>10.5 ± 0.6</td>
<td>2.3 ± 0.3</td>
<td>7.8 ± 1.0</td>
</tr>
<tr>
<td>DUDMA &amp; HEMA gel containing ETOH &amp; AH or TH</td>
<td>4</td>
<td>7.1 ± 1.7</td>
<td>2.2 ± 0.3</td>
<td>5.5 ± 0.7</td>
</tr>
<tr>
<td>DUDMA &amp; HEMA gel containing AH or TH</td>
<td>2</td>
<td>10.0 ± 1.9</td>
<td>1.4 ± 0.1</td>
<td>7.0 ± 0.7</td>
</tr>
</tbody>
</table>
Table 6  Photographic images (at day 30) of *T. rubrum* inoculated SDA plates containing nail clippings with drug-free and drug-loaded formulations cured on the surface. An example, using the ethanol-free HEMA containing formulation is shown. All the other formulations showed similar anti-fungal activity and the images are shown in the Supplementary file.

<table>
<thead>
<tr>
<th>Formulation applied on nail clipping surface</th>
<th><em>T. rubrum</em> inoculated SDA plates containing nail clippings with drug-loaded formulations cured on the surface (n=3) and the corresponding drug-free formulation cured on the surface (C)</th>
<th><em>T. rubrum</em> inoculated SDA plates containing nail clippings with drug-free formulations cured on the surface (n=3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>None (nail clipping-free &amp; formulation-free control)</td>
<td><img src="image1.png" alt="Image" /></td>
<td><img src="image2.png" alt="Image" /></td>
</tr>
<tr>
<td>DUDMA &amp; HEMA gel ± 2% w/v AH</td>
<td><img src="image3.png" alt="Image" /></td>
<td><img src="image4.png" alt="Image" /></td>
</tr>
</tbody>
</table>
Figure 1 In vivo residence of UV-cured films (± ethanol and ± drug) on the ten fingernails in six volunteers; n=60, means and standard deviations are shown. Curanail lacquer (containing amorolfine HCl) was used as a commercially available control. Abbreviations: ETOH – ethanol; AH – amorolfine HCl; TH – terbinafine HCl.
Ethyl methacrylate, MW 114, Viscosity 0.62 mPas

Isobornyl methacrylate, MW 222, Viscosity 7.40 mPas

Hydroxyethyl methacrylate, MW 130, Viscosity 6.79 mPas

Figure 2: Chemical structures and viscosities of the different methacrylate-based monomers
Figure 3: Scanning electron micrographs of the top surface (i.e. exposed to UV light), under surface (i.e. in contact with the support), and cross-sectional surface of a drug-free, ethanol-free UV-cured film (DUDMA:HEMA 85:15). Films with the other methacrylate monomers, and ± ethanol and ± drug (amorolfin HCl or terbinafine HCl) had similar micrographs.
Figure 4: Cumulative amount of drug released from the amorolfine HCl loaded UV-cured films. Means and standard deviations are shown, n=3. Abbreviations: AH, amorolfine HCl.
Figure 5: Cumulative amount of drug released from the terbinafine HCl loaded UV-cured films. Means and standard deviations are shown, n=3.
Abbreviations: TH, terbinafine HCl.
Figure 6 Cumulative amount of amorolfine HCl permeated across the nail with time from the UV-cured and Curanail® films, and the % of amorolfine HCl permeated across the nail and remaining in the nail at day 30. Means and standard deviations are shown, n=6. Abbreviations: AH, amorolfine HCl; ETOH, ethanol.

The permeation profiles for the gel containing the highest drug load (4% amorolfine HCl) was significantly different (p<0.05) to those containing 3% w/v amorolfine HCl which were similar (p>0.05), and which were in turn significantly higher (p<0.05) than the gel containing the lowest drug load (2% w/v amorolfine HCl). The steady-state flux was lowest (p<0.05) from the film with the lowest drug load.
Figure 7 Cumulative amount of terbinafine HCl permeated across the nail with time from the UV-cured films, and the % of terbinafine HCl permeated across the nail and remaining in the nail at day 30. Means and standard deviations are shown, n=6. Abbreviations: TH, terbinafine HCl; ETOH, ethanol.

The permeation profiles for the gel containing the highest drug load (6% terbinafine HCl) was significantly different (p<0.05) to those containing 3% w/v terbinafine HCl, which were similar (p>0.05), and which were in turn significantly higher (p<0.05) than the gel containing the lowest drug load (2% w/v terbinafine HCl). The steady-state flux was lowest (p<0.05) from the film with the lowest drug load.
Figure 8: Reduction of TOWL by the different UV-cured films and the Curanail lacquer film control. Means and standard deviations are shown. n=5